Physician profile
Narayan Dharel
NPI 1942464102
$47,919.49
in general payments reported to CMS, 2019-2025
45 companies · $18K in 2025
The $18K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $8,189 · 2021: $3,078 · 2022: $1,760 · 2023: $1,253 · 2024: $1,996 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $5,417 · Travel and Lodging: $2,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,845.00 |
| Food and Beverage | $5,417.14 |
| Travel and Lodging | $2,015.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $20,560.12 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $16,750.59 | 2024-2025 | Iqirvo, Bylvay |
| Abbvie INC. | $2,802.92 | 2019-2025 | Linzess, Skyrizi, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,341.85 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Echosens North America, INC. | $1,116.34 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $863.27 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $491.18 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Qol Medical, LLC | $450.67 | 2019-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $313.85 | 2020-2025 | Linzess |
| Pfizer INC. | $313.17 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $249.47 | 2024 | Zeposia |
| Genzyme Corporation | $245.79 | 2022-2025 | |
| Novo Nordisk INC | $217.94 | 2021-2025 | Wegovy |
| Covidien LP | $213.73 | 2019 | |
| Ardelyx, INC. | $184.41 | 2022-2025 | Ibsrela |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $177.38 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $165.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $142.73 | 2019-2022 | |
| Medtronic, INC. | $140.05 | 2022 | |
| Phathom Pharmaceuticals, INC. | $118.90 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $107.74 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $105.86 | 2019-2024 | Dificid |
| Shire North American Group INC | $82.50 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $76.99 | 2022-2024 | Dupixent |
| Alnylam Pharmaceuticals INC. | $66.36 | 2021-2023 | Givlaari |
| Ucb, INC. | $62.60 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $59.50 | 2019-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $59.28 | 2020-2025 | Ocaliva |
| Cook Medical LLC | $49.37 | 2023-2025 | Echotip Insight, Echotip |
| Braintree Laboratories, INC. | $49.22 | 2019-2022 | |
| Shionogi INC | $47.43 | 2019 | |
| Lilly USA, LLC | $46.45 | 2025 | Omvoh |
| Conmed Corporation | $45.45 | 2024 | Conmed Biliary |
| Allergan, INC. | $38.80 | 2019-2020 | |
| Amgen INC. | $37.38 | 2021-2023 | Avsola, Amjevita |
| Celltrion USA INC. | $24.39 | 2025 | Vegzelma |
| Boston Scientific Corporation | $22.79 | 2023 | |
| Romark Laboratories, Lc | $18.92 | 2020 | |
| Organon LLC | $15.98 | 2022 | |
| Intra-Sana Laboratories | $15.16 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Redhill Biopharma INC. | $14.08 | 2020 | |
| Olympus America INC. | $13.00 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narayan Dharel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.